JeanMarie Guenot, Ph.D., is currently the President and Chief Executive Officer of Amphivena Therapeutics, Inc., which started operating in July of 2013. This innovative company is developing antibody bifunctional therapies for hematologic malignancies. Its mission is to eradicate cancers of the blood with the use of a breakthrough therapy harnessing the immune system of the patient to destroy tumor precursors and cells. The aim is to restore the necessary cellular balance for proper blood formation, circulation and function and thus restore the “flow of life” to patients who face life-threatening illnesses.
In August 2016, Amphivena announced the acceptance by the U.S. Food and Drug Administration (FDA) of a new drug application for their AMV564, a proprietary T-cell that redirects the bispecific CD33/CD3 antibody. Plans are to initiate a Phase 1 dose escalation and expansion trial in acute myeloid leukemia patients this year. Following will be a preliminary evaluation of the antitumor activity and identification of the maximum tolerated dose along with the recommended dose to be evaluated in the clinical studies in Phase 2.
CrunchBase shows that Guenot has more than 20 years of experience in the biotechnology and pharmaceutical industries. She has worked with public and private companies, in corporate and commercial development, pharmaceutical R&D, project and alliance management, venture capital, and has expertise in building and rebuilding companies.
Previously, Dr. Guenot had a number of significant positions with major companies and has had management experience in cardiovascular and neurology diseases, oncology, autoimmune diseases, and ophthalmic diseases. She also licensed the ophthalmic indication for the oncology drug to Ophthotech.
Later she was the founder and led SKS Ocular. That was an ophthalmic start-up company incubator with the focus on dry AMD and the delivery of an ocular sustained-release drug for macular degeneration, glaucoma, and ocular inflammation.
JeanMarie Guenot earned her Ph.D. at the University of California, San Francisco and earned her MBA from the University of Pennsylvania’s Wharton School. As the CEO of Amphivena Jeanmarie has made great strides towards hiring high quality leadership.